US › Healthcare

Collegium Pharmaceutical Inc (COLL)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$35.73+0.42%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$193.5M
Revenue YoY
+8.9%
Net profit
$14.5M
Profit YoY
+499.8%
EPS
$1.76
EPS estimate
$1.52
Net margin
7.5%

EPS came in at 1.76 against a street estimate of 1.52 — a beat of 15.8%.

Key statistics

Market cap
$1.15B
P/E
17.3
Forward P/E
4.8
P/B
3.68
Book value
$9.64
EPS (TTM)
$2.06
52-week high
$50.79
52-week low
$29.70
50-day MA
$34.80
200-day MA
$39.33
Beta
0.76

Analyst view

Analysts rate Collegium Pharmaceutical Inc a buy (4 buy, 1 hold, 0 sell out of 5) with an average price target of $53.60.

Shareholding

Insiders
1.16%
Institutions
128.55%

Largest institutional holders

FundStake
BlackRock Inc15.83%
Vanguard Group Inc6.96%
HHG PLC5.63%
Amvescap Plc.4.91%
Fuller & Thaler Asset Management Inc4.62%
Renaissance Technologies Corp4.53%
State Street Corp4.39%
Eventide Asset Management, LLC4.39%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Collegium Pharmaceutical Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.